Isomab Ltd. has nominated ISM-001 as a development candidate for peripheral arterial disease. ISM-001 is a potential first-in-class therapeutic antibody designed to neutralize VEGF-A165b, the anti-angiogenic VEGF-A splice isoform that acts as a brake on development of new blood vessels leading to chronic limb threatening ischemia.
Isomab Ltd has closed a £7.5 million (US$9.4 million) seed financing round. The company is developing isoform-specific disease-modifying antibody treatments for serious and life-threatening diseases with an initial focus on peripheral ischemia.
